LONDON, July 22 -- GSK announced its sales and turnover fell by less than
expected in Q2. The Pharma giant also said there had been good growth in the
consumer, vaccine, european and emerging markets businesses and whilst the US
remains under pressure from older products going off patent, the rate of decline
has slowed down.

Talking about the improving outlook for the second half of the year, Andrew
Witty, GSK Chief Executive, said: As we go into the second half of the year I
expect to see those trends continue and, on top of that we will see significant
orders being fulfilled, for example, in pandemic vaccine orders. So H1N1 or
Swine ’Flu. We’ll also see increased volumes of Relenza, our
antiviral, being shipped as well as the kick-in of a series of new products.

The full interview and transcript are available now on

It’s free to view. All you need to do is register at, the online financial broadcaster, features
in-depth interviews, documentaries and webcasts with senior company executives.

If you would like to contact us, please email or phone

SOURCE: GlaxoSmithKline

If you would like to contact us, please email or phone